INTELLECTUAL PROPERTY INFRINGEMENT POLICY
Last Updated:
1. Preamble
This Intellectual Property Infringement Policy ("IP Policy") is a fundamental component of the contractual relationship between you ("User," "You," or "Your") and RxnCure, a trademarked brand operated by Vitmeds India Private Limited, a company duly incorporated under the provisions of the Companies Act, 2013 (hereinafter referred to as "RxnCure," "We," "Our," or "Us"). It is imperative that you read and understand this IP Policy in conjunction with the Terms and Conditions (give URL) governing the use of the domain name www.rxncure.com (hereinafter referred to as the "Website") and the RxnCure Mobile Application (available on Android and iOS).
RxnCure unequivocally respects the Intellectual Property Rights of all individuals and entities ("Persons"). As such, we vehemently prohibit not only our third-party service providers but also all other third parties from utilizing the Website to sell, distribute, circulate, post, upload, or otherwise engage in any activities that infringe upon a comprehensive array of intellectual property rights, including but not limited to copyrights, trademarks, patents, trade secrets, and other proprietary rights of any Persons.
2. Types of Intellectual Property and Possible Infringement
In the context of our Website and RxnCure Mobile Application and services, it is essential to recognize the spectrum of intellectual property rights that may be implicated. These encompass, but are not limited to:
2.1 Copyrights:
The Website may feature textual content, images, graphics, videos, software code, databases, and other materials that are protected by copyright laws. Unauthorized reproduction, distribution, display, or alteration of such copyrighted content is explicitly prohibited. This includes but is not limited to text, graphics, images, and multimedia content.
2.2 Trademarks:
The Website may incorporate trademarks, service marks, trade names, logos, and domain names, whether registered or unregistered. Unauthorized use of these trademarks, in any form, constitutes trademark infringement. This includes using similar marks or names that may cause confusion or dilution.
2.3 Patents:
Various technologies, processes, or inventions may be utilized on the Website, some of which may be protected by patents. Unauthorized use, reproduction, or distribution of patented content or products, or the unauthorized use of patented technologies, is strictly prohibited.
2.4 Trade Secrets:
RxnCure may possess trade secrets, including but not limited to proprietary algorithms, business strategies, customer data, and product formulations, which are critical to its business operations. Unauthorized disclosure, misappropriation, or use of these trade secrets is explicitly prohibited.
3. Reporting Intellectual Property Infringement
If you suspect that your intellectual property rights have been violated by any material available on the Website, it is incumbent upon you to promptly notify RxnCure by sending a comprehensive email to claims@rxncure.com (Hereinafter referred to as the "Claim"). Your Claim should include the following information:
i. The URL(s) through which the claimed infringing material is accessible on the Website or the RxnCure Mobile Application.
ii. A precise and detailed identification or description of the alleged infringing material.
iii. Exhaustive details of the intellectual property purportedly infringed, supported by concrete evidence of your ownership of the rights associated with the claimed infringing material.
iv. Your complete contact information, encompassing your full legal name, postal address, telephone number(s), and email address.
v. A solemn statement affirming your good-faith belief that the use of the claimed infringing material and the specified URL constitutes an unauthorized act by the rights owner or its licensee, and that such use amounts to an actionable infringement under applicable intellectual property laws. The statement shall also certify and declare the completeness and accuracy of the information provided by you.
4. Investigation and Remedial Action
Upon receipt of your Claim, RxnCure shall meticulously and expeditiously investigate to ascertain whether your intellectual property rights have indeed been violated, as asserted in your Claim. In the course of this investigation, RxnCure reserves the right to request additional information and documentation from you, as well as from any other relevant parties.
Post-investigation, RxnCure will deliberate and, at its sole discretion, take appropriate remedial action. The nature of such action may encompass, but is not limited to:
i. Content Removal:
If the infringement is substantiated, RxnCure may promptly remove or disable access to the infringing material.
ii. Account Suspension or Termination:
In egregious cases or repeat violations, RxnCure may suspend or terminate the accounts of users responsible for the infringement.
iii. Disclosure to Authorities:
If the situation warrants, RxnCure may disclose relevant information to law enforcement authorities for further investigation or legal action
5. False or Incomplete Claims
In circumstances where the information provided in your Claim is determined to be false, incomplete, or frivolous, RxnCure reserves the right not to take any remedial action. Additionally, RxnCure may, at its sole discretion, reactivate the URL specified in the Claim. Moreover, You may be subject to civil and potentially criminal proceedings as per applicable Indian laws.
6. Conclusion
RxnCure remains steadfast in its commitment to safeguarding Intellectual Property Rights. This comprehensive IP Policy serves as a robust framework to protect intellectual property while utilizing RxnCure's services. We urge You to approach this policy with due diligence and understanding, as it reflects our dedication to the principles of fairness, legality, and respect for the intellectual property of all Persons.
For any queries or clarifications regarding this policy, please do not hesitate to contact us at the aforementioned email address.
Effective Date: 20-04-2024
